ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

FDA Concludes Safety Review Of Novartis MS Drug Gilenya

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The U.S. Food and Drug Administration Monday said Novartis AG's (NVS, NOVN.VX) multiple-sclerosis drug Gilenya shouldn't be used in patients with a recent history of stroke or some types of heart problems, concluding a safety review of the drug. The safety review was prompted by a report last November of a 59-year-old patient dying in the U.S. less than 24 hours after taking the first dose of the drug. The agency said it continues to recommend that doctors closely monitor the hearts of patients after they have been given the first dose of the drug because the product can lower a person's heart rate temporarily. As for the patient's death, the FDA said an exact cause of death couldn't be identified. The FDA said the patient had extensive brainstem MS lesions, which also have been associated with sudden death. The FDA also said it looked at other deaths that appeared to be from cardiovascular causes in patients who had been taking Gilenya and concluded that the drug's "contribution to the death was unclear." The FDA said the drug shouldn't be used in patients who have had a stroke or heart trouble within the past six months. The agency also said the drug shouldn't be used in patients taking some kinds of antiarrhythmic heart medicines. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
10/27/201616:40:00Amgen Sees Profit Increase, Raises Guidance
10/25/201604:40:00Novartis Profit Helped by GlaxoSmithKline Joint Venture
10/25/201603:53:00Novartis Profit Helped by GlaxoSmithKline Joint Venture -- Update
10/25/201602:01:00Novartis Net Income Rose in 3rd Quarter
10/21/201608:14:00Novartis AG 3Q 2016 - Forecast
10/05/201608:20:00Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
10/02/201623:40:00Novo Nordisk Bets on Riskier Insulin Research
09/23/201613:11:00Novartis receives three new FDA approvals for the expanded use...
08/30/201618:50:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/30/201618:31:00FDA Approves Novartis's Biosimilar to Amgen's Enbrel
08/22/201608:50:00Eli Lilly, AstraZeneca Progress With Alzheimer's Drug
08/15/201610:20:00Stada Arzneimittel Braced for Investor Battle
08/05/201614:50:00AbbVie Sues Amgen Over Humira
07/27/201617:10:00Amgen Profit Rises 13%, 2016 Outlook Raised
07/26/201608:00:00Eli Lilly Revenue Rise Helped by New Products
07/25/201616:10:00Stada Arzneimittel Feels More Heat From Active Ownership
07/21/201612:50:00Amgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/20/201603:05:00Business Watch -- WSJ
07/19/201619:00:00ADRs End Lower; Ericsson Falls
07/19/201604:36:00Novartis Warns on Profit as It Boosts Investment in Heart-Failure...

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US